Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

BACKGROUND AND AIMS: The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaugain, Loïg, Cawston, Hélène, Dubois de Gennes, Coline, Sanchez Alvares, Javier, Nahon, Pierre, Mazaleyrat, Benjamin, Le Dissez, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847974/
https://www.ncbi.nlm.nih.gov/pubmed/36652428
http://dx.doi.org/10.1371/journal.pone.0280442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847974/
https://www.ncbi.nlm.nih.gov/pubmed/36652428
http://dx.doi.org/10.1371/journal.pone.0280442

Ejemplares similares